Tysabri popular among US neurologists

PharmacoEconomics & Outcomes News 628 - 14 May 2011

Tysabri popular among USneurologists

Decision Resources reports that 63% of surveyed USneurologists rate Tysabri [natalizumab] as the mosteffective therapy of the treatment of relapsing-remittingmultiple sclerosis.

According to Decision Resources, this view issupported by clinical data showing the drug’s superiorefficacy compared with other current therapies.Surveyed neurologists also reported high levels ofsatisfaction with Tysabri’s efficacy, particularly withregard to relapses, disability progression and lesions.

In contrast, none of the surveyed managed careorganisation (MGO) pharmacy directors consideredTysabri to be the most efficacious agent available for thisindication. Jonathan Searles of Decision Resourcessuggests that, "this finding may reflect a lack ofunderstanding about or experience with Tysabri".Decision Resources. The Majority of Surveyed U.S. Neurologists Selected Tysabrias the Most Effective Therapy for the Treatment of Relapsing-Remitting MultipleSclerosis, When Compared to Other Currently Available Agents. Media Release :22 Apr 2011. Available from: URL: http://www.decisionresources.com 809124028

1

PharmacoEconomics & Outcomes News 14 May 2011 No. 6281173-5503/10/0628-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved